FENDX TECHNOLOGIES INC - FDXTF STOCK NEWS

FendX Technologies (CSE: FNDX) (OTCQB: FDXTF) has signed a non-binding LOI to acquire intellectual property including two patents related to BioFoam® technology and enter a supply agreement with US BioSolutions for eco-friendly sponge wipes. The transaction involves a US$75,000 cash payment and issuance of shares worth up to $200,000. The acquired technology offers washable, reusable sponge wipes that attract and trap pathogens when combined with cleaning agents. The deal is subject to conditions including due diligence, definitive agreements, regulatory approvals, and FendX completing a $1,000,000 financing.

FendX Technologies has been granted its fifth patent, specifically a US patent (No. 12,109,586) for its REPELWRAP™ film technology. The patent, titled 'Omniphobic Surfaces with Hierarchical Structures, and Methods of Making and Uses Thereof', was registered on October 8, 2024. Licensed exclusively from McMaster University, it protects the company's nanotechnology for creating repellent surfaces that have demonstrated reduced bacterial and viral contamination in laboratory testing. This development follows recent pilot manufacturing runs with Dunmore for REPELWRAP™ film as the company prepares for real-world beta testing.

FendX Technologies has signed a Letter of Intent (LOI) with Sinelabs to explore a non-exclusive distribution agreement for FendX's future surface protection products in the United States. Sinelabs, a South Carolina-based company specializing in water treatment solutions, has an established sales network in healthcare, hospitality, and senior living facilities - markets that align with FendX's target sectors. The agreement remains subject to negotiation and execution of definitive agreements, successful product development, and regulatory approvals. REPELWRAP™ film, FendX's lead product, is expected to enter real-world testing soon.

FendX Technologies announces the grant of its Japanese patent on October 10, 2024, marking its fourth patent for REPELWRAP™ film technology. The patent, numbered JP7570358, titled 'Omniphobic Surfaces with Hierarchical Structures, and Methods of Making and Uses Thereof,' is exclusively licensed from McMaster University. The technology involves a fluoropolymer-containing material designed to reduce surface contamination by minimizing bacteria and virus adhesion. The company recently completed pilot manufacturing runs with Dunmore and is preparing for real-world beta testing.

FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) has successfully completed its pilot manufacturing phase for REPELWRAP™ film in collaboration with Dunmore International Inc. The company is now advancing to real-world assessment of the film's repelling effectiveness at various test venues. This marks a important step towards finalizing the product for commercial production.

Dr. Carolyn Myers, CEO of FendX, expressed excitement about this milestone, emphasizing the importance of real-world testing in providing valuable insights into the film's performance. The company acknowledges the significant contributions of Dunmore International Corp. and McMaster University in reaching this stage of development.

FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) has announced the publication of research results demonstrating its AI-enhanced nanotechnology's ability to detect bacterial contamination on surfaces with 96.7% accuracy. The study, conducted at McMaster University, was peer-reviewed and published in 'Advanced Functional Materials' on July 30, 2024.

The technology, derived from FendX's licensed nanotechnology, incorporates a color-changing surface coating that transitions from blue to green-yellow to indicate bacterial biofilm formation. Using AI machine learning, it achieves 100% sensitivity and 95% accuracy in contamination detection.

Carolyn Myers, President and CEO of FendX, highlighted the potential of this technology for infection prevention and control in healthcare settings. The company also announced the resignation of Andrea Mulder as COO, effective August 30, 2024.

FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) has appointed Dr. Rohit Ramchandani as an advisor to leverage his extensive public health expertise in advancing innovative solutions for pathogen control and safety. Dr. Ramchandani, a global expert in public health and infectious disease control, brings nearly two decades of experience in designing, implementing, and scaling innovative approaches for disease control and health system strengthening.

His role at FendX will be to inform, advise, and support the company's mission to develop surface protection coatings that reduce pathogen spread. Dr. Ramchandani's expertise, particularly in pandemic response and antibiotic resistance, aligns with FendX's goal of addressing growing public health threats. His appointment is expected to contribute significantly to FendX's efforts in creating groundbreaking solutions for mitigating pathogen transmission and improving overall well-being.

FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) highlights a new CDC report showing a 20% increase in infections from six antibiotic-resistant bacteria ('superbugs') in 2021 and 2022 compared to 2019. The CDC attributes this rise partly to COVID-19's impact on healthcare systems, longer hospital stays, and antibiotic overuse.

The report emphasizes the need for more effective infection prevention and control strategies. FendX, a nanotechnology company developing surface protection coatings, aims to contribute to reducing superbug spread. Dr. Carolyn Myers, CEO of FendX, states that the company is dedicated to developing innovative high-touch surface protection solutions to combat superbug transmission and enhance safety.

FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) has successfully completed a pilot scale-up run of its REPELWRAP™ film with Dunmore International Corp. The company reports that the produced film met performance expectations using a streamlined manufacturing process. Dr. Carolyn Myers, CEO of FendX, expressed satisfaction with the progress and stated that this advancement brings them closer to real-world testing with various industry partners in long-term care, fitness, and entertainment sectors.

FendX plans to conduct another pilot manufacturing run with Dunmore in the coming weeks, which they believe will be the final run before advancing to real-world testing. The company acknowledges the valuable collaboration with Dunmore and McMaster University in reaching this stage. Additionally, FendX granted 55,000 restricted share units (RSUs) to a consultant, vesting in three equal installments over the next three months.